非小細胞肺がん（NSCLC）の世界市場レポート 2024年

非小細胞肺がん（NSCLC）の市場規模は、今後数年間で急速に成長すると予想されています。 2028年には10.5%の年間複合成長率（CAGR）で299億5,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、新たな併用療法、がん治療における人工知能（AI）の統合、個別化ワクチンの拡大、調査における世界の協力、と患者中心のケアへの焦点に起因すると考えられます。予測期間中に予想される注目すべき動向としては、腫瘍学における遠隔医療の統合、リキッドバイオプシー技術の利用、診断技術の進歩、低侵襲外科技術の採用、免疫チェックポイント阻害剤の継続使用などが挙げられます。

予想されるタバコ消費量の増加により、非小細胞肺がん（NSCLC）市場の成長が促進される見込みです。喫煙、噛み、または嗅ぎによるタバコ製品の使用を伴うタバコ消費は、ニコチンやその他の有害な化学物質を体内に導入します。発がん物質を多く含むタバコの煙は肺細胞のDNAを損傷し、非小細胞肺がん（NSCLC）を含むがん細胞の突然変異や制御不能な増殖を引き起こす可能性があります。たとえば、Statistics Canadaは2022年7月に、紙巻きタバコの生産量が2021年6月と比較して5.8%増加し、2022年6月には紙巻きタバコの総販売量が14億本に達したと報告しました。その結果、タバコ消費量の上昇率はNSCLC市場の重要な推進力となっています。

非小細胞肺がん（NSCLC）市場の予想される成長は、大気汚染の増加によってさらに促進されます。大気汚染を構成する大気中の有害物質は、人間の健康に悪影響を及ぼし、炎症、DNA損傷、肺細胞の変異を通じてNSCLCのリスクを高める可能性があります。世界保健機関は2023年6月、大気と家庭の大気汚染が年間700万人の早期死亡に関連していると報告しました。さらに、約24億人が危険なレベルの家庭用大気汚染にさらされています。世界銀行は2022年9月に、大気汚染による健康被害が年間8兆1,000億米ドルに達し、これは世界のGDPの6.1％に相当するとさらに強調しました。したがって、非小細胞肺がん（NSCLC）の成長は、大気汚染の増加によって促進されると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の非小細胞肺がん（NSCLC）市場の促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の非小細胞肺がん（NSCLC）の市場規模実績と成長率、2018～2023年
• 世界の非小細胞肺がん（NSCLC）市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界の非小細胞肺がん（NSCLC）市場、タイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 扁平上皮がん
• 大細胞がん
• 腺がん
• その他
• 世界の非小細胞肺がん（NSCLC）市場、治療法別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 放射線療法
• レーザー治療
• 光線力学療法（PDT）
• その他
• 世界の非小細胞肺がん（NSCLC）市場、流通チャネル別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 病院薬局
• オンライン薬局
• その他

第7章 地域と国の分析

• 世界の非小細胞肺がん（NSCLC）市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界の非小細胞肺がん（NSCLC）市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 非小細胞肺がん（NSCLC）市場の競合情勢
• 非小細胞肺がん（NSCLC）市場企業プロファイル
  • Pfizer Inc.
  • F. Hoffmann-La Roche AG
  • Merck &Co. Inc.
  • AbbVie Inc.
  • Novartis AG

第31章 その他の大手と革新的な企業

• Sanofi SA
• Bristol-Myers Squibb Company
• AstraZeneca plc
• GlaxoSmithKline Plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Viatris Inc
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• UCB SA
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Aurobindo Pharma Limited

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在性分析

第36章 付録

Non-small cell lung cancer (NSCLC) is a form of epithelial lung cancer that originates in the lung tissues, marked by the abnormal proliferation of cells. The primary causes of NSCLC include long-term smoking, genetic mutations, exposure to air pollution, and secondhand smoke.

The main subtypes of non-small cell lung cancer (NSCLC) are squamous cell carcinoma, large cell carcinoma, adenocarcinoma, and others. Squamous cell carcinoma originates from squamous epithelial cells and can manifest in various parts of the body. A variety of therapeutic approaches are employed for NSCLC, including radiotherapy, laser therapy, photodynamic therapy (PDT), and others. These therapeutic options are distributed through different channels, including hospital pharmacies, online pharmacies, and others.

The non-small cell lung cancer (NSCLC) market research report is one of a series of new reports from The Business Research Company that provides non-small cell lung cancer (NSCLC) market statistics, including non-small cell lung cancer (NSCLC) industry global market size, regional shares, competitors with a non-small cell lung cancer (NSCLC) market share, detailed non-small cell lung cancer (NSCLC) market segments, market trends and opportunities, and any further data you may need to thrive in the non-small cell lung cancer (NSCLC) industry. This non-small cell lung cancer (NSCLC) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-small cell lung cancer (nsclc) market size has grown rapidly in recent years. It will grow from $18.02 billion in 2023 to $20.1 billion in 2024 at a compound annual growth rate (CAGR) of 11.6%. The growth observed in the historical period can be attributed to several factors, including the evolution of immunotherapy, advancements in genomic profiling and precision medicine, the expansion of clinical trials, and initiatives focused on smoking cessation.

The non-small cell lung cancer (nsclc) market size is expected to see rapid growth in the next few years. It will grow to $29.95 billion in 2028 at a compound annual growth rate (CAGR) of 10.5%. The anticipated growth in the forecast period can be attributed to emerging combination therapies, the integration of artificial intelligence (AI) in cancer treatment, the expansion of personalized vaccines, global collaborations in research, and the focus on patient-centric care. Notable trends expected in the forecast period include the integration of telemedicine in oncology, the utilization of liquid biopsy technologies, advances in diagnostic technologies, the adoption of minimally invasive surgical techniques, and the continued use of immune checkpoint inhibitors.

The anticipated rise in tobacco consumption is poised to drive the growth of the non-small cell lung cancer (NSCLC) market. Tobacco consumption, involving the use of tobacco products through smoking, chewing, or snuffing, introduces nicotine and other harmful chemicals into the body. Tobacco smoke, laden with carcinogens, can damage DNA in lung cells, leading to mutations and uncontrolled growth of cancerous cells, including non-small cell lung cancer (NSCLC). For example, Statistics Canada reported in July 2022 that cigarette production increased by 5.8% compared to June 2021, with total cigarette sales reaching 1.4 billion in June 2022. Consequently, the escalating rate of tobacco consumption is a significant driver of the NSCLC market.

The anticipated growth of the non-small cell lung cancer (NSCLC) market is further driven by increasing air pollution. Harmful substances in the atmosphere, constituting air pollution, can adversely affect human health, increasing the risk of NSCLC through inflammation, DNA damage, and mutations in lung cells. The World Health Organization reported in June 2023 that air and household air pollution were linked to 7 million premature deaths annually. Additionally, approximately 2.4 billion people are exposed to dangerous levels of household air pollution. The World Bank further highlighted in September 2022 that health damage from air pollution amounts to $8.1 trillion annually, equivalent to 6.1% of global GDP. Thus, the growth of non-small cell lung cancer (NSCLC) is expected to be propelled by increasing air pollution.

Despite the growth prospects, the non-small cell lung cancer (NSCLC) market may face hindrances due to the medication side effects associated with treatments such as immunotherapy. While immunotherapy has significantly improved survival and quality of life for NSCLC patients with fewer side effects than traditional chemotherapy, over 40% of patients, as reported by the National Cancer Institute in April 2021, experienced immune-related side effects that persisted for at least three months after stopping treatment with immune checkpoint inhibitors. This has implications for the growth of the NSCLC market.

Major companies in the non-small cell lung cancer (NSCLC) market are strategically developing multiple treatment options, including monotherapy treatments, to gain a competitive advantage. Monotherapy treatment, utilizing a single drug or therapy to address medical disorders, provides a focused approach. For instance, in June 2022, Novartis AG gained approval from the European Commission for Tabrecta (capmatinib) to treat adult patients with advanced NSCLC with METex14 skipping. This targeted therapeutic option addresses mutations causing MET exon 14 (METex14) skipping.

In August 2022, Bristol-Myers Squibb's acquisition of Turning Point Therapeutics for $4.1 billion enhances its ability to treat ROS1-positive NSCLC patients with the promising therapy, repotrectinib, developed by Turning Point Therapeutics. Repotrectinib holds the potential to improve outcomes for patients with ROS1-positive non-small-cell lung cancer. Turning Point Therapeutics specializes in developing precision medicines for NSCLC.

Major companies operating in the non-small cell lung cancer (nsclc) market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Clovis Oncology, Revolution Medicines

North America was the largest region in the non-small cell lung cancer (NSCLC) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-small cell lung cancer (nsclc) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the non-small cell lung cancer (nsclc) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The non-small cell lung cancer (NSCLC) market includes revenues earned by entities by providing services such as targeted therapies, radiation therapies, imaging tests, biopsy, bronchoscopy, and lung function tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-small cell lung cancer (NSCLC) market also includes sales of chemotherapy drugs such as cisplatin, carboplatin, and pemetrexed epidermal growth factor receptor (EGFR) inhibitors such as erlotinib, afatinib, and gefitinib, as well as pain medications. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Small Cell Lung Cancer (NSCLC) Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-small cell lung cancer (NSCLC) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-small cell lung cancer (NSCLC)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-small cell lung cancer (NSCLC) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Type: Squamous Cell Carcinoma; Large Cell Carcinoma; Adenocarcinoma; Other Types
• 2) By Therapy: Radiotherapy; Laser Therapy; Photodynamic Therapy (PDT); Other Therapies
• 3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Other Distribution Channels
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Non-Small Cell Lung Cancer (NSCLC) Market Characteristics

3. Non-Small Cell Lung Cancer (NSCLC) Market Trends And Strategies

4. Non-Small Cell Lung Cancer (NSCLC) Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Non-Small Cell Lung Cancer (NSCLC) Market Size and Growth

• 5.1. Global Non-Small Cell Lung Cancer (NSCLC) Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Non-Small Cell Lung Cancer (NSCLC) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Non-Small Cell Lung Cancer (NSCLC) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Non-Small Cell Lung Cancer (NSCLC) Market Segmentation

• 6.1. Global Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Squamous Cell Carcinoma
• Large Cell Carcinoma
• Adenocarcinoma
• Other Types
• 6.2. Global Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Radiotherapy
• Laserthearpy
• Photodynamic Therapy (PDT)
• Other Therapies
• 6.3. Global Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Other Distribution Channels

7. Non-Small Cell Lung Cancer (NSCLC) Market Regional And Country Analysis

• 7.1. Global Non-Small Cell Lung Cancer (NSCLC) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Non-Small Cell Lung Cancer (NSCLC) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market

• 8.1. Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Non-Small Cell Lung Cancer (NSCLC) Market

• 9.1. China Non-Small Cell Lung Cancer (NSCLC) Market Overview
• 9.2. China Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Non-Small Cell Lung Cancer (NSCLC) Market

• 10.1. India Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Non-Small Cell Lung Cancer (NSCLC) Market

• 11.1. Japan Non-Small Cell Lung Cancer (NSCLC) Market Overview
• 11.2. Japan Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Non-Small Cell Lung Cancer (NSCLC) Market

• 12.1. Australia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Non-Small Cell Lung Cancer (NSCLC) Market

• 13.1. Indonesia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Non-Small Cell Lung Cancer (NSCLC) Market

• 14.1. South Korea Non-Small Cell Lung Cancer (NSCLC) Market Overview
• 14.2. South Korea Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Non-Small Cell Lung Cancer (NSCLC) Market

• 15.1. Western Europe Non-Small Cell Lung Cancer (NSCLC) Market Overview
• 15.2. Western Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Non-Small Cell Lung Cancer (NSCLC) Market

• 16.1. UK Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Non-Small Cell Lung Cancer (NSCLC) Market

• 17.1. Germany Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Non-Small Cell Lung Cancer (NSCLC) Market

• 18.5. France Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.6. France Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.7. France Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Non-Small Cell Lung Cancer (NSCLC) Market

• 19.9. Italy Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.10. Italy Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.11. Italy Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Non-Small Cell Lung Cancer (NSCLC) Market

• 20.13. Spain Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.14. Spain Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.15. Spain Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market

• 21.1. Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market Overview
• 21.2. Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Non-Small Cell Lung Cancer (NSCLC) Market

• 22.1. Russia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Non-Small Cell Lung Cancer (NSCLC) Market

• 23.1. North America Non-Small Cell Lung Cancer (NSCLC) Market Overview
• 23.2. North America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Non-Small Cell Lung Cancer (NSCLC) Market

• 24.1. USA Non-Small Cell Lung Cancer (NSCLC) Market Overview
• 24.2. USA Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Non-Small Cell Lung Cancer (NSCLC) Market

• 25.1. Canada Non-Small Cell Lung Cancer (NSCLC) Market Overview
• 25.2. Canada Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Non-Small Cell Lung Cancer (NSCLC) Market

• 26.1. South America Non-Small Cell Lung Cancer (NSCLC) Market Overview
• 26.2. South America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Non-Small Cell Lung Cancer (NSCLC) Market

• 27.1. Brazil Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Non-Small Cell Lung Cancer (NSCLC) Market

• 28.1. Middle East Non-Small Cell Lung Cancer (NSCLC) Market Overview
• 28.2. Middle East Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Non-Small Cell Lung Cancer (NSCLC) Market

• 29.1. Africa Non-Small Cell Lung Cancer (NSCLC) Market Overview
• 29.2. Africa Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Non-Small Cell Lung Cancer (NSCLC) Market Competitive Landscape And Company Profiles

• 30.1. Non-Small Cell Lung Cancer (NSCLC) Market Competitive Landscape
• 30.2. Non-Small Cell Lung Cancer (NSCLC) Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. F. Hoffmann-La Roche AG
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Merck & Co. Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. AbbVie Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Novartis AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Non-Small Cell Lung Cancer (NSCLC) Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca plc
• 31.4. GlaxoSmithKline Plc
• 31.5. Takeda Pharmaceutical Company Limited
• 31.6. Eli Lilly and Company
• 31.7. Amgen Inc.
• 31.8. Viatris Inc
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. Regeneron Pharmaceuticals Inc.
• 31.11. Astellas Pharma Inc.
• 31.12. UCB S.A.
• 31.13. Sun Pharmaceutical Industries Ltd.
• 31.14. Dr. Reddy's Laboratories Ltd.
• 31.15. Aurobindo Pharma Limited

32. Global Non-Small Cell Lung Cancer (NSCLC) Market Competitive Benchmarking

33. Global Non-Small Cell Lung Cancer (NSCLC) Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Non-Small Cell Lung Cancer (NSCLC) Market

35. Non-Small Cell Lung Cancer (NSCLC) Market Future Outlook and Potential Analysis

• 35.1 Non-Small Cell Lung Cancer (NSCLC) Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Non-Small Cell Lung Cancer (NSCLC) Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Non-Small Cell Lung Cancer (NSCLC) Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer